Assembly-line GLP-1 telehealth platform
AIOS
The real moat is not the questionnaire, it is turning obesity prescribing into a repeatable assembly line that lets each clinician supervise far more patients. ClinicOS turns rules like BMI cutoffs, contraindication checks, refill timing, titration steps, and side effect escalation into structured paths, so the routine patient journey can move from ad click to shipped medication without staff manually re reading charts or sending one off messages.
-
This is how GLP-1 telehealth scales faster than a normal clinic. The core loop is paid acquisition, short intake form, clinician signoff, pharmacy dispense, monthly refill. When that loop is standardized in software, revenue can grow with marketing spend instead of growing linearly with care staff.
-
AIOS is more vertically integrated than many telehealth peers because the same workflow handles prescribing and fulfillment. That matters in GLP-1 care because dose changes, refill timing, cold chain shipping, and side effect follow up all have to stay coordinated every month, not just at the first prescription.
-
The closest comparables show the tradeoff clearly. Ro and Hims built large telehealth businesses by wrapping operations around a hero drug category, but AIOS goes narrower and deeper around GLP-1s alone, using one shared ops layer across Fella, Delilah, and Bolt rather than stacking many conditions into one brand.
Going forward, the winners in GLP-1 telehealth are likely to look less like online doctors and more like software run pharmacies with clinicians supervising the exception queue. If AIOS keeps proving that routine obesity care can be processed safely through one operating system, that model can expand across new countries and eventually capture more of the economics around fulfillment and drug supply.